EN DE

AK Medical Holdings (1789) Fair Value & Analysis

Healthcare · HK · Market cap HK$5.5B

AM AK Medical Holdings 1789 · HK
PriceHK$5.64
Fair ValueHK$7.11
Upside+26.1%
Quality72/100
Watch AK Medical Holdings for free, get notified when fair value or trend changes. Watch for free
Healthy Growth
Highly profitable · 22.9% net margin
Low debt · generates free cash flow
2.07% dividend yield
Ranks above peers (12/14)
Wide moat 70/100
Evidence: High Range HK$5.00 – HK$8.83 Share as image

Fair value as of: Aug 5, 2026

From 26 valuation models · updated 5 days ago

Fair value updated Aug 5, 2026, revised from HK$7.06 to HK$7.11 (+0.7%) since Jul 2, 2026. Share price +4.1% over the past month.

A solid business, screening 26% undervalued on our models.

What matters now

  • The rarer combination: high quality (72/100) AND below fair value. That earns a closer look rather than a quick verdict.
  • Our model range runs from HK$5.00 (bear) to HK$8.83 (bull), base HK$7.11. The closer the price sits to the lower half, the larger the margin of safety.
  • Quality 72/100 (solid quality) with high evidence: the data supports the verdict.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

HK$14.79 HK$3.39 Fair Value HK$7.11 Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 5, 2026.

How to read this chart

60‑month range HK$3.39 – HK$14.79 · fair‑value band HK$5.00 – HK$8.83 · the HK$5.64 price screens below the HK$7.11 fair value. Dashed = 300-day average. As of Aug 5, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

AK Medical Holdings (1789) currently trades at HK$5.64, while our model-based Fair Value estimate is HK$7.11, implying the stock looks roughly 26.1% undervalued today. The Quality Score stands at 72/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, AK Medical Holdings generated revenue of HK$1.5B at a net margin of 22.9%. Revenue grew 14.4% year over year. It earns a return on equity of 12.2%. The balance sheet holds a net cash position of HK$230M. Fundamentals as of Aug 5, 2026

Our scenario range runs from HK$5.00 (bear case) to HK$8.83 (bull case); at HK$5.64, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 20% below its 52-week high and 19% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at 26%, 1789 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model BearBaseBull Evidence
Highest evidence
Growth DCF HK$4.23 HK$7.97 HK$13.67 80
Residual Income HK$2.45 HK$2.84 HK$5.56 76
Rev-Margin DCF HK$3.62 HK$6.31 HK$10.06 74
All 26 models by family
DCF Models
FCF DCF HK$4.35 HK$7.57 HK$15.46 38
Owner Earnings HK$4.65 HK$8.94 HK$16.90 31
5Y Revenue Exit HK$3.62 HK$6.41 HK$10.36 39
5Y EBITDA Exit HK$4.65 HK$8.69 HK$14.06 41
5Y P/E Exit HK$5.00 HK$9.47 HK$14.93 38
10Y Revenue Exit HK$3.73 HK$6.52 HK$11.19 36
10Y EBITDA Exit HK$4.52 HK$8.23 HK$14.45 37
10Y P/E Exit HK$4.75 HK$8.81 HK$15.22 35
Earnings-Based
Graham-Dodd HK$2.15 HK$12.67 HK$17.64 54
Lynch FV HK$3.59 HK$5.13 HK$6.67 50
PEG = 1.0 HK$3.59 HK$5.13 HK$6.67 46
EPV HK$3.04 HK$3.47 HK$3.84 59
Dividend Discount
Gordon GGM HK$0.5900 HK$1.17 HK$1.77 70
DDM Multi-Stage HK$0.5900 HK$1.01 HK$1.24 61
Multiples
P/E Multiple HK$5.22 HK$6.96 HK$8.70 63
P/S Multiple HK$3.63 HK$4.84 HK$6.05 58
P/B Multiple HK$4.04 HK$5.38 HK$6.73 55
EV/EBIT HK$4.79 HK$6.28 HK$7.76 53
EV/EBITDA HK$5.03 HK$6.59 HK$8.15 54
EV/Revenue HK$3.25 HK$4.50 HK$5.74 43
Asset-Based
NCAV (Graham) HK$1.36 HK$1.82 HK$2.72 50
Growth DCF
Growth DCF HK$4.23 HK$7.97 HK$13.67 80
Rev-Margin DCF HK$3.62 HK$6.31 HK$10.06 74
Economic Profit
Residual Income HK$2.45 HK$2.84 HK$5.56 76
ROIC Compounder HK$3.26 HK$4.47 HK$5.55 72
Growth Earnings
Growth-Adj P/E HK$5.38 HK$7.69 HK$10.00 68

Widest divergence: DCF Models (HK$8.23) versus Dividend Discount (HK$1.01). Highest evidence: Growth DCF (80).

Key figures & financial health

Revenue (TTM) HK$1.5B
Revenue growth (YoY) +14.4%
Net margin 22.9%
Return on equity 12.2%
Free cash flow HK$316M FY2025
P/E ratio 14.6
More key figures
Operating margin 26.2%
EPS (TTM) HK$0.1400
Dividend yield 2.1%
EPS growth (YoY) +32.3%
Net cash HK$230M FY2025

Figures from reported company fundamentals · as of Aug 5, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 72/100

Of which business quality 70 · Market factors (momentum, volatility) 44

Profitability 54
Margins and returns on capital today
Quality Growth 61
Are margins and returns improving?
Cashflow 75
Earnings quality: real cash, not paper profit
Fin. Strength 87
Balance sheet, leverage, solvency risk
Investment 60
Disciplined investing over empire-building
Low Volatility 71
Calm price path (market factor)
Momentum 32
Price trend over the last 3–12 months (market factor)
52W Momentum 35
Distance to the 52-week high (market factor)
Net Issuance 81
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

AK Medical Holdings Limited, an investment holding company, designs, develops, produces, and markets orthopedic joint implants and related products in the People's Republic of China, the United Kingdom, and internationally.

Full company description

AK Medical Holdings Limited, an investment holding company, designs, develops, produces, and markets orthopedic joint implants and related products in the People's Republic of China, the United Kingdom, and internationally. It offers knee, hip, and spinal and trauma replacement implants; and 3D-printed products, such as 3D-printed hip and knee replacement implants, 3D-printed spinal and trauma implants, as well as customized joint, pelvic, spinal and trauma implant products and customized value-added surgical services and orthopedic surgical robots. The company also distributes third party orthopedic products; and offers surgical instruments and medical irrigators. Its principal customers include distributors, hospitals, physicians and surgeons, and patients. The company was founded in 2003 and is based in Beijing, the People's Republic of China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

AK Medical Holdings reported revenue of HK$1.5B in FY2025 versus HK$761M in FY2021, a compound +18.1%/yr. Reported net income was HK$339M in FY2025, compounding +38.3%/yr from FY2021.

Growth Quality 85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
HK$1.5B
Latest YoY
+10.1%
Avg. growth/yr (3Y)
+12.1%
Avg. growth/yr (5Y)
+7.4%
Avg. growth/yr (11Y)
+23.3%
Revenue +18.1%/yr
FY21 HK$761M
FY22 HK$1.1B
FY23 HK$1.1B
FY24 HK$1.3B
FY25 HK$1.5B
Net income +38.3%/yr
FY21 HK$92.6M
FY22 HK$205M
FY23 HK$182M
FY24 HK$274M
FY25 HK$339M

Watch 1789: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "AK Medical Holdings Fair Value". https://www.fairvalue-calculator.com/stock/1789

Peer Group

Medical Devices · 351 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 72 · Top 25%
Fair Value upside +26% · Top 25%
Return on equity (TTM) 12% · Top 25%
Return on assets 7% · Top 25%
Net margin (TTM) 23% · Top 25%
Operating margin (TTM) 26% · Top 25%
Revenue growth 14% · Above median
Dividend yield (TTM) 2.1% · Above median
Debt / equity 0.00× · Lower than median

Valuation Multiples vs Medical Devices median · lower = cheaper

P/E (TTM) 14.6× · Cheaper than 75% of peers
P/B 1.88× · Pricier than median
P/S (TTM) 3.70× · Pricier than median
P/FCF 2.2× · Cheaper than median
EV/EBITDA 11.0× · Cheaper than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 68 · sector 0
FUTURE 72 · sector 27
PAST 49 · sector 8
HEALTH 100 · sector 97
DIVIDEND 41 · sector 38

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 5, 2026).

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $100.68 $74.79 -26%
Stryker Corporation SYK $316.44 $186.28 -41%
Medtronic plc MDT $83.56 $65.57 -22%
Boston Scientific Corporation BSX $43.04 $38.44 -11%
Edwards Lifesciences Corporation EW $85.73 $41.02 -52%
Siemens Healthineers AG SHL €34.59 €33.87 -2%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥149.43 ¥147.63 -1%
Shanghai United Imaging Healthcare Co 688271 ¥109.00 ¥43.60 -60%
Demant A/S DEMANT kr 276.60 kr 161.17 -42%
Getinge AB GETIB kr 206.80 kr 192.14 -7%

Compare AK Medical Holdings with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is AK Medical Holdings (1789) overvalued or undervalued?
As of Aug 5, 2026, our model estimates a fair value of HK$7.11 versus a price of HK$5.64, about +26% (undervalued).
What is the fair value of 1789?
Our model-based fair value for AK Medical Holdings is HK$7.11 (as of Aug 5, 2026), built from audited fundamentals. The current price is HK$5.64.
What is the quality score of 1789?
AK Medical Holdings has a Quality Score of 72/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of AK Medical Holdings (1789)?
AK Medical Holdings reported trailing-twelve-month revenue of about HK$1.5B (latest available figure, as of Aug 5, 2026).
What is the net profit margin of 1789?
The net profit margin of AK Medical Holdings is about 22.9%, meaning it keeps roughly 22.9% of revenue as net income. Based on the latest reported figures.
Does AK Medical Holdings pay a dividend?
AK Medical Holdings currently shows a dividend yield of about 2.07% relative to its recent price (as of Aug 5, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track AK Medical Holdings and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.